8-K: Coya Therapeutics Secures $4.2M Milestone for ALS Trial Progress

Coya Therapeutics announced the receipt of a $4.2 million milestone payment from Dr. Reddy's Laboratories, triggered by the first patient dosing in its ALSTARS trial for amyotrophic lateral sclerosis (ALS).

Summary

• Coya Therapeutics, Inc. received a $4.2 million milestone payment on December 16, 2025.
• This payment was made under the Development and License Agreement, dated December 5, 2023, with Dr. Reddy's Laboratories Ltd. and its affiliate, Dr. Reddy's Laboratories SA.
• The milestone was triggered by the dosing of the first patient in the company's ALSTARS trial, which is evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).
• The first patient dosing in the ALSTARS trial was previously announced on December 9, 2025.

Sentiment

Score: 8

Explanation: The receipt of a $4.2 million milestone payment for achieving a significant clinical trial milestone (first patient dosing) is a strong positive development. It provides non-dilutive funding and validates the progress of a key therapeutic program for a serious disease like ALS.

Positives

• Receipt of a $4.2 million non-dilutive cash inflow, strengthening the company's financial position.
• Successful achievement of a significant clinical development milestone (first patient dosing in ALSTARS trial for COYA 302).
• Validation of the Development and License Agreement with Dr. Reddy's Laboratories, indicating ongoing partnership and progress.
• Advancement of the COYA 302 program for ALS, a critical step in its clinical development.

Future Outlook

The receipt of the milestone payment indicates continued progress in the clinical development of COYA 302 for ALS, with the ALSTARS trial now underway. This suggests a commitment to advancing the therapeutic candidate through clinical stages.

Management Comments

• The company duly caused this report to be signed on its behalf by Arun Swaminathan Ph.D., Chief Executive Officer.

Industry Context

The biopharmaceutical industry heavily relies on strategic partnerships and milestone payments to fund costly drug development. This event highlights Coya Therapeutics' progress in the competitive ALS treatment landscape, a disease area with significant unmet medical needs. Milestone payments are common in such agreements, providing non-dilutive capital to advance clinical programs.

Stakeholder Impact

• Shareholders: Positive impact due to non-dilutive cash inflow and progress in a key clinical program, potentially increasing company valuation and reducing future financing needs.
• Patients (ALS): Positive outlook as the ALSTARS trial for COYA 302 advances, offering potential new treatment options for amyotrophic lateral sclerosis.
• Partners (Dr. Reddy's Laboratories): Indicates successful collaboration and progress under the existing Development and License Agreement.

Next Steps

• Continued enrollment and progression of the ALSTARS trial evaluating COYA 302 for ALS.
• Further clinical development and potential future milestones related to the Development and License Agreement.

Key Dates

Recommendation

While the receipt of a $4.2 million milestone payment is a positive development, signaling progress in the ALSTARS trial and providing non-dilutive capital, it represents a single event in a long and high-risk drug development process. The overall investment thesis for Coya Therapeutics remains largely dependent on the future clinical trial results of COYA 302. Investors should hold, acknowledging this positive step, but await further clinical data and broader financial performance before making more aggressive investment decisions.

Keywords

Coya Therapeutics, COYA, Dr. Reddy's Laboratories, ALS, Amyotrophic Lateral Sclerosis, ALSTARS trial, COYA 302, Milestone Payment, Clinical Trial, Biotechnology, Pharmaceuticals, Neurological Disorders